NCT00539578View on ClinicalTrials.gov

Treatment of Patients With Anxiety Disorder (0777-022)

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

MK0777

Duration of Treatment: 4 weeks

DRUG

Comparator: placebo (unspecified)

Duration of Treatment: 4 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00539578 - Treatment of Patients With Anxiety Disorder (0777-022) | Biotech Hunter | Biotech Hunter